A checklist-based method for improving COPD care for the elderly in general practice: study protocol for a cluster randomized controlled trial using electronic health records

Anna Kowalczyk, Izabela Zakowska*, Ewa Andrzejewska, Katarzyna Kosiek and Maciek Godycki-Cwirko

Abstract

Background: The third most frequent chronic condition, and the fourth most common cause of death, in Poland is chronic obstructive pulmonary disease (COPD). The diagnosis and treatment of COPD is the responsibility of the general practitioner (GP); the GP also serves as gatekeeper, referring patients to the other levels of public health care system when necessary. Undertreatment of COPD can result in a greater frequency of exacerbations and hospitalizations. Elderly patients require special attention due to the increased prevalence of COPD and systemic comorbidities. However, both the occurrence of exacerbations and the quality of life of the patients may be improved by developing and implementing guidelines for practice and ensuring their adherence. This proposal concerns the development of a checklist-based educational program to assist general practitioners in managing COPD patients.

Methods: No less than eighty-four general clinics in the Lodz region, Poland (28 clusters in each of three study arms), will be identified, randomized, and included in the trial. The trial will be based on anonymized data in electronic health records within the national public health care system.

The educational intervention program will consist of GPs in two intervention arms being provided with a COPD management checklist: those in the first intervention arm with receive the checklist once at the beginning, while those in the second with receive it twice. The third (control) arm receives standard care without the checklist. The study used the International Code of Diseases (ICD)-10 for COPD. The primary aim is to determine the effect of interventions delivered to general practitioners (GPs) in primary health care. These interventions are aimed at decreasing the hospitalization of elderly patients with medical code J-44 (COPD) as the main reason for hospital admission.

Discussion: The results of this trial will be directly applicable to primary care in Poland and add new data to the growing body of evidence regarding interventions aimed at improving chronic illness care.

(Continued on next page)
**Contribution to the literature**

- This document describes the design and implementation of a pragmatic study to assess the effectiveness and implementation of a strategy based on a structured checklist in primary care.
- The impact of the checklist on care in COPD will be determined using Big Data methods.
- The clinical effectiveness of repetition of COPD checklist exposure in primary care will be assessed.

**Introduction**

**Background**

Caring for patients with chronic obstructive pulmonary disease (COPD) presents a substantial challenge for general practitioners (GPs). COPD is a non-reversible lung condition characterized by shortness of breath, chronic cough with sputum production, emphysema, and systemic pulmonary inflammation.

Although data on its prevalence in the general population is limited, the true prevalence of COPD among the Danish population is believed to be 9% (95% CI 8–10%), with the highest prevalence observed among current smokers (23%) and former smokers (17%) as well as among seniors (total = 18%; men = 21%; women = 15%) [1].

In Australia, approximately 5% of patients in general practice were found to suffer from COPD; this number rises to approximately 10% among patients aged 65 years or above [2].

Although the scope of the problem is recognized in Poland, relatively little concrete research data exists, especially concerning elderly patients in primary care. It is estimated that the prevalence of COPD is approximately two million out of a population of about 38 million; this places COPD as the third most widespread chronic condition in the country and the fourth most common cause of death [3].

However, international studies indicate that the prevalence of COPD in Poland may be considerably higher than previously anticipated (10% of the examined population) [4].

In Poland, almost everyone registered with the national public health care system (NFZ) is also registered with a GP. The GP acts as gatekeeper, referring patients with diagnostic or treatment problems to the other levels of the public health care system. However, it is possible that some mistakes may occur with diagnosis and treatment. Under-treatment can result in unnecessary symptom burden, impaired COPD control, and more frequent exacerbations and hospitalization, while over-treatment may lead to increased healthcare costs and potential iatrogenic effects [5].

Elderly patients are at greatest risk of developing COPD and its components: emphysema, chronic bronchitis, and bronchiectasis. Bacterial and viral infections also play a role in acute exacerbations of COPD, and elderly patients are at greater risk of infection by antibiotic-resistant bacteria [6].

A Danish study indicates substantial room for improvement in GP clinics [8].

Other studies indicate that even the routine implementation of community health assessment and improved planning measures can lead to improved health outcomes [9]. The annual healthcare costs for primary care for these patients are estimated to be approximately 53.6 million euros. Various interventional approaches have been used [10].

COPD exacerbations significantly impact health-related quality of life and disease progression, and healthcare costs associated with severe exacerbation-related hospitalization range from $7000 to $39,200 in the USA. However, the timely and appropriate application of maintenance pharmacotherapy, particularly dual bronchodilators for maximizing bronchodilation, can significantly reduce exacerbations, and multidisciplinary...
disease-management programs including pulmonary rehabilitation, follow-up appointments, aftercare, inhaler training, and patient education can reduce hospitalizations and readmissions for patients with COPD [11].

However, few physicians are aware of practice guidelines and continuing medical education (CME) programs [12]. Current guidelines are still poorly adhered to by GPs, and generally, little is known of the role of specific non-clinical interventions in facilitating GP care for COPD patients. To remedy this, the EU-funded TICD project, a cluster randomized controlled trial (RCT), was performed to identify possible determinants of COPD care and tailored interventions to facilitate better implementation in general practice [13]. Such intervention appears feasible [14].

The present study will identify the most effective method for delivering an educational intervention to general practitioners based on a simple consensus process.

This protocol has been written in line with the SPIRIT standard [15].

Objectives
1. To determine the effect of intervention aimed at decreasing the hospitalization of elderly patients with J-44 as the main reason for hospital admission, compared to those receiving usual care
2. To optimize the management of elderly COPD patients
3. To examine whether intervention 1 and intervention 2 are effective, pragmatic, and feasible within the primary care setting

Trial design
The trial is planned as a 1-year, three-arm, pragmatic, cluster randomized trial (CRCT). It will compare the effectiveness of interventions in two arms (single intervention and double intervention) at reducing the hospitalization of seniors in primary care with the J-44 code as a main reason for admission, compared to those experiencing usual care.

Methods/design
Study setting
Eighty-four GP clinics in the Lodz voivodship in Poland will be identified at baseline using data from the National Health Fund’s (Narodowy Fundusz Zdrowia, NFZ) electronic medical records (EHR). They will be randomly selected using the following criteria: clinics with at least 30 patients per clinic, aged 65 years and older with COPD. Patients with COPD will be identified by the ICD-10 code J-44 in NFZ electronic medical records; exacerbations will be defined as cases hospitalized with the J-44 code as the main reason for admission.

Observation period
The study will include data for 1 year, from March 2020 until February 2021. Data extraction and analysis will take place from March until June 2021 (see Fig. 1).

The endline data for the clinic and patients will be collected after 1 year. We will consider additional data collections from other time points based on the development of the COVID situation.

Sample size
A minimum number of 84 GP clinics with at least 30 J-44 patients per clinic is required to provide a sufficient sample size for a three-arm cluster randomized controlled trial: 84 clusters and at least 2520 subjects are needed (28 clusters in each study arm) to detect a difference of 0.026 between mean event rates of hospitalization with ICD-10 code J-44 as the main reason for admission. This assumes a 25% reduction in total number of events after the intervention in the first arm (receiving checklist once) and 50% reduction in total number of events after the interventions in the second arm (receiving checklist twice) compared to the control group not receiving any intervention (standard care). It is also assumed the tests will have 80% power, a two-tailed alpha of 0.05, and intra-cluster correlation of 0.01.

Data collected from electronic health records in 2016 indicate that the mean event rate of “hospitalized with ICD-10 code J-44 as the main reason for admission” in the control group is 0.105, and the standard deviation is 0.306. The unadjusted sample size was calculated for differences between three means for one-way ANOVA.

To compare the individuals hospitalized with the J-44 code in the three arms after 1 year, the difference between the mean event rates of the three groups was calculated according to Donner and Klar [16].

A standard sample size formula was used to calculate the initial unadjusted sample size requirements, followed by appropriate adjustment for clustering by general practice according to Campbell et al. [17], with expected small clustering effect (ICC = 0.01) [18, 19].

To prevent loss to follow-up among practices/participants, an enlarged overall sample size will be deemed appropriate to ensure adequate power.

Randomization
The clinics will be randomized without repeating by a Data Scientist (not involved in the trial) using a computer system. Each GP clinic will be allocated randomly to one of three equal-sized arms: two intervention arms and a control arm by Data Scientist.
| TIMEPOINT | -t₁ | t₀=0 | t₂=6 | t₃=12 | t₄ | tₛ |
|-----------|-----|------|------|-------|----|----|
| II 2020   | II 2020 | IX 2020 | III 2021 | III-VI 2021 | VII 2021 |

**STUDY PERIOD**

| Baseline | Start. Sending checklist to first and second arms (month) | Sending checklist to second arm (month) | End. Finishing the observation period (month) | Data collection | Close-out |
|----------|----------------------------------------------------------|----------------------------------------|---------------------------------------------|----------------|-----------|

**ENROLMENT:**

| Eligibility screen | Randomisation |
|--------------------|---------------|
| X                  | X             |

**INTERVENTIONS:**

**FIRST INTERVENTION**
- Sending checklist to first arm: once at the beginning of the study

|                     | X |
|---------------------|---|

**SECOND INTERVENTION**
- Sending checklist to second arm: at the beginning of the study and after six months

|                     | X | X |
|---------------------|---|---|

**POSTINTERVENTION:**

| Obtaining data | Data cleaning | Data analysis | Preparing papers |
|----------------|---------------|---------------|------------------|
| X              |               | X             | X                |

**Fig. 1** The schedule of the study
The clinics from the intervention arms will find out that they are enrolled when they receive the letters with interventions. The letters will be sent simultaneously. The control arm will only use usual care and has no intervention.

**Blinding**

Participants in this trial will be anonymized rather than blinded. Because of the nature of the interventions, it is not possible to blind the GP participants in the clinics. Outcome assessment will not be blinded as the researchers will be aware of practice arm allocation. The Data Scientist will not be blinded, because she will be independent of the research team.

**Interventions**

The educational intervention program will consist of providing GPs in two intervention arms with a COPD management checklist (Additional file 1).

In the first intervention arm, the checklist will be delivered at the beginning of the study (March 2020); in the second arm, it will be delivered at the beginning of the study and repeated after 6 months. Clinics that are randomized to the control arm will not receive the COPD management checklist, and GPs will treat all patients according to standard care.

The checklist was developed by authors on the basis of GOLD guidelines [20] and the 2015 Physician Quality Reporting System (PQRS) Implementation Guide Centers for Medicare & Medicaid Services [21].

**Outcomes**

The primary outcome of the study will be the effect of the interventions on the proportion of “hospitalization with the J-44 code as a main reason for admission,” and the proportion of deaths of elderly COPD patients, registered within practices after 1 year.

Primary outcome at the patient level will be assessed as the proportion of cases between the three arms (intervention 1, intervention 2 and control) at the end of the 1-year study period. Proportion of cases (event rates) of binary variables of exacerbation outcome will be assessed based on “hospitalization with the J-44 code as a main reason for admission,” and the proportion of deaths of elderly COPD patients.

The effect of the educational intervention will be evaluated using logistic 2-level regression analysis, based on odds ratios (OR) and 95% confidence limits.

We will examine the association between intervention and COPD exacerbation, using a case-control approach. Cases will be selected among COPD exacerbation after 1 year. Control subjects will be selected among COPD patients.

Secondary outcome at the patient level will be the proportion of the control and intervention arms regarding the specific short- and long-acting drugs prescribed after 1 year.

**Data collection methods**

Patient data will be obtained from Big Data databases, such as the patient electronic health record system from the National Health Fund (NFZ).

**Data management**

Depersonalized data will be obtained and subjected to quality control and cleaning.

The structure of the obtained data will be hierarchical. Individual patient data will be anonymized. Patients will be nested within PC clinics. The approach to missing data will be determined once the data is obtained.

Big Data cleansing process will be performed according to SAS Data Management Methodology. This methodology covers a step-by-step process, and it covers tasks such as data management, data quality, data integration, data migrations, and master data management.

Study variables: demographic and characteristics will include age; gender; residence code; “hospitalized, with the J-44 code as the main reason for admission”; death; specific short- and long-acting medication prescribed; and number of GPs.

**Statistical methods for analysis**

Post-intervention analysis will be performed.

The following data will be analyzed in the post-intervention patients: hospitalization with the J-44 code as the main reason for admission, and use of medication. The analysis will be based on multilevel regression models.

**Categorical predictors**

Educational interventions after 1 year in two arms, and an arm with standard care (control), age and gender.

**Test statistics for primary outcome and dependent variable**

The effect of the educational interventions will be evaluated using two-level logistic regression models with a dependent binary variable (case-control, cross-sectional analysis), with patients nested within practices.

Data regarding hospitalization will be collected directly from patient electronic health records held by the National Health Fund (NFH—the state health insurance system). Patients registering exacerbation, defined as “hospitalization of patients with the J-44 as a main reason for admission,” will be classed as cases. Control subjects will be collected from electronic health records held by the NFH, defined as COPD (J-44), age over 65, with low treatment cost, and no constantly reimbursed

---

Kowalczyk et al. Trials (2021) 22:161

Page 5 of 7
drugs. Data will be collected after the 1-year study period (cross-sectional) within the Lodz voivodeship.

Descriptive statistics and logistic regression will be employed. The level of statistical significance will be $p < 0.05$.

**Discussion**

Our methods will be used to quantitatively evaluate the impact of the proposed educational program on reducing COPD exacerbations among COPD patients presenting at primary care clinics compared with existing standard care.

Its main limitations relate to the specificity and sensitivity of the COPD coding, gaps in databases, and short period of observation. In addition, some selection bias may exist in the study, since small practices will be excluded. Furthermore, the COVID epidemic could also distort the effects of the intervention and influence the results. Finally, the participation of the National Health Fund and the sending of letters may be disrupted.

Nevertheless, we believe that the results will be directly relevant and applicable to primary care in Poland. If the implementation is effective, then wide-scale application would be warranted. We will consider additional data collection time points to extend further analysis to account for the impact of COVID.

**Trial status**

The trial is currently in the interventions phase.

**ClinicalTrials.gov** identifier: NCT04301505. Registered on 10 March 2020, https://clinicaltrials.gov/ct2/show/NCT04301505

Protocol Version 9: 16 January 2021.

Date recruitment began: March 2020.

Estimate of the date when recruitment will be completed: March 2021.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05103-0.

If the intervention is found to be beneficial, we plan to make the checklist available to primary care clinics.

**Authors' contributions**

The study concept and design was conceived by AK, IZ, EA, KK, and MGC. Analysis will be performed by Data Scientist IZ (SAS 9.4 analyses; Statistica 13.1; MLwiN ver. 2.24 analyses) and MGC. MGC, AK, IZ, and KK prepared the first draft of the manuscript. All authors provided edits and critiqued the manuscript for intellectual content. The authors read and approved the final manuscript.

**Funding**

This article was prepared within the research project no.2016/21/B/NZ7/02052 funded by Narodowe Centrum Nauki (National Science Centre Poland).

Funding source had no role in the study design and will have no role in collection, management, analysis, writing of the report, interpretation of data, or decision to submit results.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

The study protocol has been approved by the Bioethical Committee of the Medical University of Lodz (RNN/426/19/KE, 12 December 2019). This trial will not require individual patient consent, because it will use data from electronic health records. Observatory study is planned using NFZ patient data. No additional patient consent will be needed. Our findings will be published in peer-reviewed journals and reports.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**References**

1. Hansen JG, Pedersen L, Ovend K, Omland O, Jensen HK, Sorensen HT. The prevalence of chronic obstructive pulmonary disease among Danes aged 45-84 years: population-based study. Copd J Chronic Obstruct Pulmon Dis. 2008;5(6):347–52.

2. Henderson J, Harrison C, Miller G. Management of COPD in general practice. Aust Fam Physician. 2012;41(11):841.

3. Płyczewski R, Bednarek M, Jonczak L, Zieliński J. Prevalence of COPD in Warsaw population. Pneumonol Alergol Pol. 2003;71(8):329–35.

4. Nizankowska-Mogilnicka E, Mejza F, Halmi KL, Vollmer WM, Skucha W, Harat R, et al. Prevalence of COPD and tobacco smoking in Malopolska region—results from the BOLD study in Poland. Pol Arch Med Wewn. 2007;117(9):402–10.

5. May SM, Li JT. Burden of chronic obstructive pulmonary disease: healthcare costs and beyond. Allergy Asthma Proc. 2015;36(1):4–10.

6. Albertson TE, Louie S, Chan AL. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J Am Geriatr Soc. 2010;58(3):570–9.

7. Jadad A. Chronic obstructive pulmonary disease (COPD) and old age? Chron Respir Dis. 2011;8(2):143–51.

8. Schermer TR, Akkermans RP, Crockett AJ, van Montfort M, Grootens-Stekelenburg J, Stout JW, Pieters W. Effect of e-learning and repeated performance feedback on spirometry test quality in family practice: a cluster trial. Ann Fam Med. 2011;9(4):330–6.

9. Loekeke A, Soenegaard J, Hansen MK, Poulsen SV, Roslind L, Lange P. Real life management of chronic obstructive pulmonary disease (COPD) in general practice (GP) in Denmark. Eur Respir J. 2015;46PA1812.

10. van Bokhoven MA, Kok G, van der Weijden T. Designing a quality improvement intervention: a systematic approach. Qual Saf Health Care. 2003;12(3):215–20.
11. Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health Syst Pharm. 2020; 77(4):259–68.

12. Foster JA, Yawn BP, Maziar A, Jenkins T, Rennard SI, Casebeer L. Enhancing COPD management in primary care settings. MedGenMed. 2007;9(3):24.

13. Godycki-Cwirko M, Zakowska I, Kosiek K, Wensing M, Krawczyk J, Kowalczyk A. Evaluation of a tailored implementation strategy to improve the management of patients with chronic obstructive pulmonary disease in primary care: a study protocol of a cluster randomized trial. Trials. 2014;15:109.

14. Krause J, Van Lieshout J, Klop R, Huntink E, Aalhus E, Flottorp S, et al. Identifying determinants of care for tailoring implementation in chronic diseases: an evaluation of different methods. Implement Sci. 2014;9:102.

15. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

16. Donner A, Klar N. Analysis of binary outcomes. In: Arnold, editor. Design and analysis of cluster randomization trials in health research; 2000. p. 79–110.

17. Campbell MK, Thomson S, Ramsay CR, MacLennan GS, Grimshaw JM. Sample size calculator for cluster randomized trials. Comput Biol Med. 2004; 34(2):113–25.

18. Elley CR, Kerse N, Chondros P, Robinson E. Intraclass correlation coefficients from three cluster randomised controlled trials in primary and residential health care. Aust N Z J Public Health. 2005;29(5):461–7.

19. Sandelowsky H, Krakau I, Modin S, Ställberg B, Nager A. Case method in COPD education for primary care physicians: study protocol for a cluster randomised controlled trial. Trials. 2017;18(1):197.

20. GOLD. Report. 2020 Global Strategy for Prevention, Diagnosis and Management of COPD.; 2020. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 14 Apr 2020.

21. CMS. 2016 Physician quality reporting system (PQRS): implementation guide. Centers for Medicare & Medicaid Services (CMS); 2016. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Downloads/2016_PQRS_ImplementationGuide.pdf Accessed 14 Apr 2020.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.